AstraZeneca PLC (LSE: AZN, NASDAQ: AZN) has taken a significant reputational hit following the failure of its Wainua drug trial, according to analysts at Jefferies.
The broker argues the damage is less about the financial impact and more about a meaningful dent to management’s credibility with investors.
AstraZeneca shares fell 9% in the wake of the news, placing the stock at the top of the FTSE 100 fallers list for the session.
Jefferies rates AstraZeneca as a ‘buy’ with a target price of 18,000p, and forecasts peak Wainua sales in the heart indication of $4 billion at a 60% probability.
On a risk-adjusted basis, that figure translates to around 250p per share, representing roughly 2% of the company’s net present value.
Despite the relatively modest valuation hit, Jefferies believes the initial share price decline will likely be double the drug’s actual contribution to value.
The broker identified a key factor that complicated the trial outcome: a 24% drop-in of rival drug tafamidis during the study period.
That influx pushed the proportion of patients on the competing treatment from 57% at the start of the trial to around 80%, significantly muddying Wainua’s ability to demonstrate added benefit on top of existing therapy.
By comparison, the rival HELIOS-B trial conducted by Pfizer saw only 53% of patients on tafamidis, making a direct comparison difficult and the result harder to interpret cleanly.
On a more encouraging note, patients taking Wainua alone showed a 29% reduction in events, a nominally significant result that Jefferies said was broadly in line with findings from HELIOS-B.
The credibility problem stems from the high confidence management had publicly placed in the trial hitting its primary endpoint and demonstrating benefit in combination use.
AstraZeneca is widely regarded as a company capable of designing near-watertight clinical trials, meaning a failure of this nature raises uncomfortable questions for investors.
The timing of the setback adds further pressure, as the market has limited appetite for uncertainty heading into the next major catalyst for the stock.
Jefferies flagged the AVANZAR lung cancer data readout, expected around July or August, as another contested event that investors will be watching closely.
The broker suggested the stock may struggle to recover meaningfully until that particular overhang is resolved and investor confidence is restored.
On the broader investment case, Jefferies was clear that the Wainua failure does not threaten AstraZeneca’s $80 billion 2030 sales target, leaving the long-term outlook intact despite the near-term turbulence in sentiment.